← Leaderboards
Siddarth Selvaraj
Arima Genomics, Llc
$8,905,700
Attributed
$10,070,626
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2016–24$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,070,626 · 5
By mechanism
R44$9,505,934 · 3
R43$564,692 · 2
Top collaborators
- Jesse R Dixon2 shared
- Louise Chang Laurent2 shared
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologyGenomeGenomicsSamplingPerformanceInnovationCellsCostBasePersonalized Medicine3-DimensionalMarketingSuccessCommercializationProgramsAdoptionResearch And DevelopmentDiagnosisPrecision MedicineGenesNew TechnologyNext Generation SequencingPreservationLaboratories
Grant awards (11)
Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumors$1,913,603
R44 · FY2024 · CA · contact PI
Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumors$2,069,712
R44 · FY2023 · CA · contact PI
Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from FFPE tumor biopsies$999,273
R44 · FY2021 · CA · contact PI
Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from FFPE tumor biopsies$999,273
R44 · FY2020 · CA · contact PI
Commercialization of HaploSeq as a Service (HaaS) for generating chromosome-span phased genome and exome sequence information$174,249
R44 · FY2019 · HG · contact PI
Commercialization of HaploSeq as a Service (HaaS) for generating chromosome-span phased genome and exome sequence information$1,573,140
R44 · FY2018 · HG · contact PI
Commercialization of a low-cost user-friendly DNA preparation kit that produces chromosome-span contiguity from conventional short-read sequencingââ for a wide range of applications$928,154
R44 · FY2018 · HG · contact PI
Commercialization of a low-cost user-friendly DNA preparation kit that produces chromosome-span contiguity from conventional short-read sequencingââ for a wide range of applications$848,530
R44 · FY2017 · HG · contact PI
Maximal resolution and full-length phasing for next-generation MHC-typing$49,539
R43 · FY2017 · AI · contact PI
Non-invasive determination of complete fetal genomes from cfDNA using HaploSeq$290,577
R43 · FY2016 · HD · contact PI
Maximal resolution and full-length phasing for next-generation MHC-typing$224,576
R43 · FY2016 · AI · contact PI